---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-132736"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:13:38.034656+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics atacicept Phase 3 IgAN trial meets primary endpoint; 46% proteinuria reduction

## Summary
- Atacicept achieved 46% reduction from baseline in UPCR, 42% vs placebo (p<0.0001) at week 36.
- Safety profile favorable and comparable to placebo in the ORIGIN Phase 3 trial of 431 adults.
- Vera plans to submit BLA for accelerated approval to FDA in Q4 2025; commercial launch targeted for 2026.
- Trial continues blinded to assess eGFR over two years, expected completion in 2027.
- No eGFR results shared at this time per FDA guidance; full results to be presented at ASN Kidney Week.

## SEC filing metadata
- accession: 0001193125-25-132736
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312525132736/0001193125-25-132736-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312525132736/d916346d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-132736
- JSON: https://secwatch.observer/filing/0001193125-25-132736.json
- Plain text: https://secwatch.observer/filing/0001193125-25-132736.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.